Pancragen Research Overview (also known as Pancragen peptide, Ala-Glu-Asp-Gly tetrapeptide, Khavinson pancreatic bioregulator)
A peptide studied for pancreatic cell wellness, insulin sensitivity support, and glucose-handling pathway regulation. Research interest includes metabolic health and pancreatic function preservation in aging and metabolic stress models.
What Is Pancragen?
Pancragen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting the pancreas — both its endocrine function (insulin and glucagon secretion from islets of Langerhans) and its exocrine function (digestive enzyme production from acinar cells). It is designed to restore normal pancreatic cellular activity that declines with aging.
Pancreatic Aging
The pancreas undergoes significant age-related changes: exocrine acinar cell number and activity decline, reducing digestive enzyme output and contributing to malabsorption. Beta cell mass and insulin secretory capacity decrease, contributing to the impaired first-phase insulin response characteristic of age-related glucose dysregulation. Pancragen is designed to restore normal activity in both pancreatic compartments.
Research Applications
Animal studies have demonstrated improved pancreatic histological scores, preserved islet architecture, and normalized insulin secretion parameters in aged animals treated with Pancragen. Studies also document improved exocrine enzyme production. Russian clinical research has examined Pancragen for age-related pancreatic insufficiency and borderline glucose regulation in elderly subjects. It is sometimes combined with Svetinorm (liver bioregulator) for comprehensive metabolic health support.
Mechanism of Action
DNA / chromatin interaction and epigenetic modulation: Pancragen is proposed to penetrate cellular membranes, localize to the nucleus, and interact with DNA and histones. It may bind chromatin complexes, alter promoter methylation patterns at key genes (PDX1, NGN3), and shift transcription toward a more youthful or regenerative profile. Murine studies show upregulation of transcription factors critical for pancreatic endocrine cell maturation — Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4 — supporting beta cell differentiation and functional maintenance.
Pancreatic endocrine function and glucose metabolism: Non-human primate studies (IM, 10-day course) showed improved glucose disappearance rate and normalized insulin and C-peptide dynamics. A small human study in elderly type 2 diabetic subjects showed reduced fasting glucose, improved OGTT response, and reduced insulin resistance index. Laboratory models further support modulation of insulin and glucagon secretion and regulation of digestive enzyme production.
Anti-apoptotic and cellular aging effects: Pancragen reduces pro-apoptotic p53 expression and increases anti-apoptotic Mcl-1 in cell models, suggesting a cytoprotective role under metabolic and oxidative stress. Antioxidant potential has been hypothesized — either through free radical scavenging or upregulation of endogenous defenses. Plasma half-life is expected to be short (minutes to a few hours, like other ultrashort tetrapeptides), but functional metabolic effects persist up to several weeks post-cycle, consistent with transcriptional and epigenetic changes that outlast peptide plasma presence.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Pancreatic Endocrine Function & Glucose Metabolism
Non-human primate study (10-day IM course) showed normalized glucose disappearance rate and improved insulin and C-peptide dynamics after glucose challenge. Small human T2D trial in elderly subjects reported reduced fasting glucose, improved OGTT results, and reduced insulin resistance index — authors concluded Pancragen is a promising approach to correcting insulin resistance in elderly individuals.
Insulin Resistance Correction in Elderly T2D
Russian clinical data from elderly type 2 diabetic subjects showed significant reductions in fasting glucose, oral glucose tolerance improvements, and decreased insulin resistance index after a 10-day Pancragen course. Represents the strongest clinical signal in the Pancragen literature.
Pancreatic Endocrine Function & Glucose MetabolismSupported Research
Pancreatic Cell Differentiation & Epigenetic Regulation
Murine models show upregulation of key transcription factors for endocrine cell maturation: Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Promoter methylation changes at PDX1 and NGN3 suggest a shift toward more youthful gene expression profiles in pancreatic cells. These effects position Pancragen as a research tool for epigenetic studies in pancreatic tissue.
Exocrine Pancreatic Function
Animal studies document improved exocrine enzyme production and preserved acinar cell histological scores alongside endocrine improvements. Age-related decline in digestive enzyme output represents a secondary research target alongside the endocrine/metabolic work.
Pancreatic Cell Differentiation & Epigenetic RegulationPreliminary Data
Cellular Protection & Anti-Apoptotic Effects
Cell culture and laboratory models show reduced p53 expression and increased anti-apoptotic Mcl-1, suggesting a cytoprotective role in pancreatic cells under metabolic or oxidative stress. Hypothesized antioxidant potential (free radical scavenging or endogenous antioxidant upregulation) also noted in preclinical work. No human evidence for these mechanisms.
Longevity & Multi-Cycle Metabolic Resilience
Bioregulator framework proposes that 2–3 cycles/year of Pancragen maintains or gradually improves metabolic resilience and pancreatic function in aging models. Evidence is limited to non-randomized, primarily Russian observational data with small samples and short follow-up. Long-term human RCT data does not exist.
Cellular Protection & Anti-Apoptotic EffectsPreclinical Only
Research Protocols (Educational Only)
Disclaimer
Pancragen is not an approved drug. All dosing reflects Russian bioregulator studies, non-human primate experiments, and RUO practice — not medical recommendations. Cycle length and break between cycles differ significantly from most other peptides; follow the 10–20 day on / 2–6 month off pattern from the literature.
| Goal / Context | Dose | Frequency / Duration | Route |
|---|
| T2D / Insulin Resistance (elderly humans) | 10 mg | Once daily × 10 days | SubQ / IM |
| Pancreatic Endocrine Function (NHP) | 50 mcg/animal | Once daily × 10 days | IM |
| Metabolic / Aging Research (RUO) | 10 mg | Once daily × 10–20 days | SubQ / IM |
Cycle Pattern
10–20 days on → 2–6 months off. Most RUO protocols and bioregulator literature recommend 2–3 cycles per year. The extended break is consistent with the model that epigenetic and transcriptional changes accumulate over a short course and persist for weeks — repeated short cycles with long breaks are the norm across the Khavinson bioregulator family.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Course | 10 mg | Once daily during course | SubQ |
| Short Intensive | 10 mg | Once daily during course | SubQ |
| Maintenance | 10 mg | Once daily during course | SubQ |
Peptide Interactions
Pancragen targets pancreas/insulin; Livagen and Ovagen target liver and GI. Often paired conceptually in multi-organ aging and metabolic protocols to address broader metabolic decline. No formal interaction data.
Conceptually stacked to address multiple aging tissues simultaneously (pancreas + pineal + thymus). Evidence is mostly Russian and observational. No formal safety data for combined use.
Pancragen's epigenetic endocrine support might theoretically complement incretin-based therapies. No formal interaction data exists; overlapping glucose-lowering mechanisms require glycemic monitoring.
Pancragen reduced glucose and improved insulin sensitivity in elderly T2D trials. Simultaneous use with insulin or hypoglycemic agents could potentiate glucose-lowering effects — close glycemic monitoring required in any clinical context.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Well tolerated in published studies — non-human primate and elderly T2D trials reported no serious adverse events; Pancragen was generally well tolerated at 10 mg/day IM/SubQ for 10 days.
No dependence or withdrawal phenomena reported — consistent with the rest of the Khavinson bioregulator family.
Glycemic monitoring recommended when co-administered with insulin, oral hypoglycemics, or other glucose-lowering agents — Pancragen reduced fasting glucose and insulin resistance in T2D subjects.
Long-term epigenetic effects are unknown — off-target effects on other tissues or theoretical impact on tumor biology have not been rigorously evaluated in long-term studies.
Evidence base is limited — the bulk of Pancragen data comes from small, non-randomized Russian studies with short follow-up, plus animal and cell work. No large Western RCTs exist.
Not FDA-approved — sold exclusively as an RUO research peptide. Not intended for clinical use in humans outside a research protocol.
Do Not Use If:
Active hypoglycemia or poorly controlled diabetes without medical supervision (glucose-lowering effects are documented)
Concurrent use with insulin or hypoglycemic agents without glycemic monitoring
Use outside of research settings — Pancragen is RUO only and not intended for clinical self-administration
Seek Medical Attention If:
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Severe or unusual symptoms following administration
Always consult a licensed physician before and during use
Unexpected changes in blood glucose levels
Quality Indicators
Verified
Peptide identity (KEDW / Lys-Glu-Asp-Trp) confirmed by mass spectrometry
Reputable RUO vendors confirm tetrapeptide sequence by MS. HPLC purity ≥99% with documented COA required.
Verified
Lyophilized white/off-white powder; clear colorless solution after reconstitution
Visual inspection at reconstitution. Solutions should be clear and colorless — cloudiness, particulates, or color indicate degradation or contamination.
Caution
Storage: 2–8°C; protect from light and moisture
Lyophilized powder stable at –20°C for long-term storage. Reconstituted solution typically stable up to 28 days refrigerated at 2–8°C.
CAUTION — NOT RECOMMENDED
Supplements or capsules marketed without clear peptide identity or third-party testing
Products lacking MS confirmation of KEDW sequence, HPLC purity, or sterility documentation carry unpredictable identity and dosing risk. Capsule supplements marketed as "Pancragen" without peptide identity confirmation are especially common.
Reported Research Timeline
01During the active course (Days 1–10 to 1–20) (reported in cited studies): Pancragen (Ala-Glu-Asp-Gly tetrapeptide) acts on pancreatic acinar and islet cells through chromatin-level epigenetic normalization. The primary research outcomes tracked during active courses include changes in fasting glucose, serum amylase and lipase activity, and pancreatic enzyme secretory capacity. Effects emerge progressively across the 10–20 day course window.
02Weeks 2–4 post-course (reported in cited studies): Improved pancreatic enzyme secretion (amylase, lipase, protease) and better digestive efficiency — tracked as improved digestion of fats and proteins — are the hallmark early post-course findings in Khavinson research. Blood glucose regulation parameters begin normalizing in subjects with pre-existing mild dysregulation.
03Months 1–3 (sustained metabolic effects) (reported in cited studies): Khavinson longitudinal data document persisting improvements in fasting glucose, HbA1c trajectory, and digestive enzyme capacity for 3–6 months post-course. These effects are most pronounced in older subjects with measurably declining baseline pancreatic function. The semi-annual repeat protocol is designed to maintain these improvements.
04Long-term (repeated courses) (reported in cited studies): In Khavinson aging cohort studies, subjects receiving regular pancreatic bioregulator courses showed slower age-related decline in digestive enzyme production and more stable glycemic control compared to controls over 3–5 year observation windows. As with all Khavinson peptides, independent replication outside the Russian research system is limited.
Research Citations
- Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
Goncharova ND, Ivanova LG, Oganyan TE — Adv Gerontol, 2015
- Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys
Goncharova ND, Ivanova LG, Oganian TÉ — Adv Gerontol, 2014
- Peptide regulation of aging — Khavinson bioregulator family review
Khavinson VKh, Linkova NS et al. — Bull Exp Biol Med, 2013
- Short peptides regulate gene expression, protein synthesis and replicative lifespan of human fibroblasts
Khavinson VKh et al. — Bull Exp Biol Med, 2014
- Peptide bioregulators as a new class of geroprotectors: from laboratory research to clinical studies
Khavinson V, Linkova N, Diatlova A, Trofimova S — Biomedicines, 2021
Research Focus
Pancreatic function, Insulin regulation, Digestive enzyme production, Anti-aging, Beta cell support
Verified Vendors Carrying Pancragen
Frequently Asked Questions
What should researchers watch for with Pancragen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Pancragen?
During the active course (Days 1–10 to 1–20) (reported in cited studies): Pancragen (Ala-Glu-Asp-Gly tetrapeptide) acts on pancreatic acinar and islet cells through chromatin-level epigenetic normalization. The primary research outcomes tracked during active courses include changes in fasting glucose, serum amylase and lipase activity, and pancreatic enzyme secretory capacity. Effects emerge progressively across the 10–20 day course window.
How is Pancragen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →